semaglutide gastroparesis lawsuit in louisiana glp-1 legal team law office law office louisiana Ozempic Lawsuit: May 2026 Blindness and Gastroparesis Claims-mvanhaasteren.nl Louisiana lawmakers are considering a – louisiana semaglutide gastrointestinal obstruction class

Chaurasiya RS, Hebbar HU

Key Points: GI symptoms are the most common adverse effects, ranging from expected nausea and vomiting to gastroparesis and, rarely, functional obstruction Delayed gastric emptying has important airway implications and a cautious approach to airway management is warranted Biliary disease is one of the most clinically significant complications, particularly early in treatment and with rapid weight loss Pancreatitis is rare, and current evidence does not support a strong causal relationship EDKA and AKI are uncommon but important to recognize in the right context Conclusions: GLP-1 receptor agonists have transformed the management of diabetes and obesity, with clear benefits in weight loss, glycemic control, and cardiovascular outcomes

SCOTUS - Hernandez vs

While the science is for populations, health care is individual and decisions around food and/or medicine should be made with the considered advice of health care professionals

However, subcutaneous injections are considered a much safer and more convenient form of peptide application in experimental settings

No powders, no mixing, no mess just grab, chew, and go